Immunobiology Unit 10 Review: Mucosal and Cutaneous Immunity

Key Concepts and Definitions

• Mucosal immunity protects the body's mucosal surfaces (respiratory tract, gastrointestinal tract, urogenital tract) from pathogens and harmful substances
• Cutaneous immunity defends the skin against external threats such as bacteria, viruses, and fungi
• Innate immunity provides rapid, non-specific defense mechanisms (physical barriers, chemical barriers, cellular components)
• Adaptive immunity develops specific, long-lasting protection through T cells and B cells
  • T cells directly attack infected cells and regulate immune responses
  • B cells produce antibodies that neutralize pathogens and mark them for destruction
• Microbiome refers to the diverse community of microorganisms that inhabit the body's surfaces and play a crucial role in maintaining health
• Immune tolerance allows the immune system to distinguish between self and non-self, preventing autoimmune reactions
• Mucosal-associated lymphoid tissue (MALT) consists of specialized immune cells and structures located in mucosal surfaces (Peyer's patches, tonsils, adenoids)
• Skin-associated lymphoid tissue (SALT) includes immune cells and structures in the skin (Langerhans cells, dermal dendritic cells, skin-draining lymph nodes)

Anatomy of Mucosal and Cutaneous Surfaces

• Mucosal surfaces are lined by epithelial cells that form a physical barrier against pathogens
  • Epithelial cells are connected by tight junctions, adherens junctions, and desmosomes
  • Goblet cells secrete mucus, which traps and removes pathogens
• Skin is composed of two main layers: epidermis and dermis
  • Epidermis is the outermost layer and consists of keratinocytes that produce keratin, a protective protein
  • Dermis contains blood vessels, hair follicles, sweat glands, and immune cells
• Mucosal surfaces have specialized structures for immune surveillance and response
  • Peyer's patches in the small intestine monitor gut contents and initiate immune responses
  • Tonsils and adenoids in the throat and nasal passages trap and eliminate respiratory pathogens
• Skin has unique immune features
  • Acidic pH and antimicrobial peptides (defensins, cathelicidins) inhibit microbial growth
  • Sweat and sebum create a hostile environment for pathogens
• Mucosal and cutaneous surfaces are constantly exposed to a wide range of antigens (food proteins, commensal bacteria, environmental allergens)
• Lymphatic vessels drain mucosal and cutaneous tissues, transporting antigens and immune cells to regional lymph nodes for further processing

Innate Immune Mechanisms

• Physical barriers (mucus, epithelial cells, skin) prevent pathogen entry and colonization
• Chemical barriers (antimicrobial peptides, enzymes, low pH) create an inhospitable environment for microbes
• Pattern recognition receptors (Toll-like receptors, NOD-like receptors) on immune cells detect conserved microbial structures and initiate inflammatory responses
• Innate immune cells (macrophages, dendritic cells, neutrophils) phagocytose and destroy pathogens
  • Macrophages are long-lived cells that engulf and digest microbes and cellular debris
  • Dendritic cells are specialized antigen-presenting cells that bridge innate and adaptive immunity
• Natural killer (NK) cells recognize and kill virus-infected and tumor cells
• Complement system consists of plasma proteins that opsonize pathogens, promote inflammation, and lyse bacterial cells
• Innate lymphoid cells (ILCs) are tissue-resident cells that produce cytokines and regulate mucosal homeostasis
  • ILC1s produce IFN-γ and promote Th1 responses
  • ILC2s secrete IL-5 and IL-13, contributing to Th2 responses and allergic inflammation
  • ILC3s produce IL-17 and IL-22, supporting Th17 responses and epithelial barrier function

Adaptive Immune Responses

• T cells and B cells are the main components of adaptive immunity
• T cells develop in the thymus and are classified into two main subsets: CD4+ helper T cells and CD8+ cytotoxic T cells
  • CD4+ T cells differentiate into various effector subsets (Th1, Th2, Th17, Treg) based on cytokine signals
  • CD8+ T cells directly kill infected or malignant cells through the release of cytotoxic granules (perforin, granzymes)
• B cells mature in the bone marrow and differentiate into plasma cells that secrete antibodies
  • Antibodies neutralize toxins, block pathogen entry, and promote phagocytosis through opsonization
  • IgA is the predominant antibody class in mucosal secretions and provides frontline defense against pathogens
• Mucosal and cutaneous immune responses are initiated in local lymphoid tissues (Peyer's patches, tonsils, skin-draining lymph nodes)
  • Dendritic cells present antigens to naive T cells, inducing their activation and differentiation
  • Activated T cells migrate to effector sites (lamina propria, skin) and perform their respective functions
• Memory T and B cells persist after infection or vaccination, providing rapid and enhanced protection upon re-exposure to the same pathogen
• Regulatory T cells (Tregs) maintain immune homeostasis by suppressing excessive or inappropriate immune responses

Microbiome Interactions

• Mucosal and cutaneous surfaces harbor diverse microbial communities that shape immune responses
• Commensal bacteria compete with pathogens for nutrients and space, preventing their overgrowth
• Microbial metabolites (short-chain fatty acids, indoles) promote epithelial barrier function and regulate immune cell development
• Microbiota influences the balance between pro-inflammatory and regulatory immune responses
  • Segmented filamentous bacteria (SFB) induce Th17 cells in the gut, which protect against fungal and bacterial infections
  • Bacteroides fragilis produces polysaccharide A (PSA), which stimulates Treg differentiation and maintains immune tolerance
• Dysbiosis, an imbalance in the microbiome composition, is associated with various immune-mediated disorders (inflammatory bowel disease, atopic dermatitis, psoriasis)
• Probiotics are live microorganisms that confer health benefits when administered in adequate amounts
  • Lactobacillus and Bifidobacterium species are commonly used probiotics that modulate immune responses and improve gut barrier function
• Prebiotics are non-digestible food components that selectively stimulate the growth and activity of beneficial gut bacteria
  • Fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS) are prebiotic fibers that promote the growth of Bifidobacteria and Lactobacilli

Immune Disorders and Diseases

• Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract
  • Crohn's disease can affect any part of the GI tract and is associated with Th1 and Th17 responses
  • Ulcerative colitis is limited to the colon and is driven by Th2 responses
• Celiac disease is an autoimmune disorder triggered by gluten consumption, leading to small intestine damage and nutrient malabsorption
• Food allergies result from an inappropriate immune response to food proteins, mediated by IgE antibodies and mast cell activation
• Atopic dermatitis (eczema) is a chronic inflammatory skin condition associated with Th2 responses and skin barrier dysfunction
• Psoriasis is an autoimmune skin disorder characterized by the hyperproliferation of keratinocytes and Th17-driven inflammation
• Primary immunodeficiencies are genetic disorders that impair the development or function of immune cells
  • X-linked agammaglobulinemia (XLA) is caused by mutations in the BTK gene, leading to B cell deficiency and recurrent infections
  • Severe combined immunodeficiency (SCID) affects both T and B cell development, resulting in life-threatening infections
• Acquired immunodeficiencies are caused by external factors such as HIV infection, malnutrition, or immunosuppressive medications

Clinical Applications and Treatments

• Vaccines stimulate adaptive immune responses to prevent infections
  • Oral vaccines (polio, rotavirus) induce mucosal immunity in the gut
  • Intranasal vaccines (FluMist) generate protective immunity in the respiratory tract
• Immunotherapy harnesses the immune system to treat cancer and autoimmune diseases
  • Checkpoint inhibitors (anti-CTLA-4, anti-PD-1) enhance T cell responses against tumor cells
  • Chimeric antigen receptor (CAR) T cell therapy genetically modifies patient's T cells to target and eliminate cancer cells
• Monoclonal antibodies are lab-produced antibodies that target specific molecules
  • Infliximab (anti-TNF-α) is used to treat IBD and rheumatoid arthritis by reducing inflammation
  • Dupilumab (anti-IL-4Rα) is approved for atopic dermatitis and asthma, blocking Th2 responses
• Fecal microbiota transplantation (FMT) involves the transfer of healthy donor feces to restore the gut microbiome in patients with recurrent Clostridium difficile infection
• Probiotics and prebiotics are used to modulate the microbiome and alleviate symptoms of gastrointestinal disorders
• Immunosuppressive drugs (corticosteroids, methotrexate) are used to control excessive immune responses in autoimmune diseases and transplant recipients

Current Research and Future Directions

• Investigating the role of the microbiome in the development and progression of immune-mediated diseases
  • Identifying specific microbial strains or metabolites that influence immune responses
  • Developing targeted microbiome-based therapies (probiotics, prebiotics, FMT) for personalized treatment
• Exploring the mechanisms of immune tolerance and its breakdown in autoimmune disorders
  • Elucidating the factors that trigger the loss of self-tolerance
  • Developing strategies to restore immune tolerance (Treg therapy, antigen-specific immunotherapy)
• Advancing cancer immunotherapy
  • Combining checkpoint inhibitors with other treatment modalities (chemotherapy, radiation) to improve efficacy
  • Developing novel CAR T cell therapies targeting solid tumors and minimizing side effects
• Studying the impact of environmental factors (diet, stress, pollution) on mucosal and cutaneous immunity
  • Investigating the role of the exposome (total environmental exposures) in shaping immune responses
  • Identifying potential interventions to mitigate the harmful effects of environmental factors on immune health
• Developing next-generation vaccines
  • Designing vaccines that provide broad protection against multiple strains or serotypes of pathogens
  • Exploring new vaccine platforms (mRNA, viral vectors) to improve safety and efficacy
• Translating basic research findings into clinical applications
  • Conducting clinical trials to assess the safety and efficacy of novel immunotherapies
  • Implementing precision medicine approaches to tailor immune-based treatments to individual patients based on their genetic and immunological profiles